Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 21.5088 USD -0.79%
Market Cap: 2.6B USD
Have any thoughts about
Catalyst Pharmaceuticals Inc?
Write Note

Catalyst Pharmaceuticals Inc
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Catalyst Pharmaceuticals Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Tax Provision
-$25.4m
CAGR 3-Years
N/A
CAGR 5-Years
-129%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
-$2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$63m
CAGR 3-Years
68%
CAGR 5-Years
48%
CAGR 10-Years
30%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$449m
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
0%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$739.4m
CAGR 3-Years
-9%
CAGR 5-Years
-31%
CAGR 10-Years
-61%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$314.9m
CAGR 3-Years
33%
CAGR 5-Years
-20%
CAGR 10-Years
3%
No Stocks Found

Catalyst Pharmaceuticals Inc
Glance View

Market Cap
2.5B USD
Industry
Biotechnology
Economic Moat
Wide

Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions. Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.

CPRX Intrinsic Value
23.4581 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Catalyst Pharmaceuticals Inc's Tax Provision?
Tax Provision
-25.4m USD

Based on the financial report for Jun 30, 2024, Catalyst Pharmaceuticals Inc's Tax Provision amounts to -25.4m USD.

What is Catalyst Pharmaceuticals Inc's Tax Provision growth rate?
Tax Provision CAGR 5Y
-129%

Over the last year, the Tax Provision growth was 13%.

Back to Top